{"schema_version":"secwatch.filing_event.v1","accession":"0001739104-26-000027","form_type":"8-K","ticker":"ELAN","cik":"0001739104","company_name":"Elanco Animal Health Inc","filed_at":"2026-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.831647+00:00","generated_at":"2026-05-14T22:49:30.530688+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Elanco Q1 revenue +15% to $1.37B, raises FY2026 guidance across all metrics","bullets":["Q1 revenue $1.37B (+15% reported, +10% organic constant currency); adjusted EPS $0.40 vs $0.37 prior year.","Full-year 2026 guidance raised: revenue $5,010-$5,085M, adj. EBITDA $975-$1,005M, adj. EPS $1.03-$1.09.","Q2 2026 guidance: revenue $1,300-$1,325M, adj. EBITDA $240-$260M, adj. EPS $0.25-$0.28.","Innovation revenue target raised to $1.2B; net leverage target improved to 3.0x-3.2x.","Credelio Quattro and Zenrelia post strong share gains; closed AHV International acquisition Apr 30."],"urls":{"canonical":"https://secwatch.observer/filing/0001739104-26-000027","json":"https://secwatch.observer/filing/0001739104-26-000027.json","markdown":"https://secwatch.observer/filing/0001739104-26-000027.md","text":"https://secwatch.observer/filing/0001739104-26-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739104/000173910426000027/0001739104-26-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739104/000173910426000027/elan-20260506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T22:49:30.530688+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b06708637a9e3168275e8ed10a3d399e34b39ea0","claim":"Elanco Animal Health Inc reported first quarter of 2026 results: revenue $1,371 million, net income $57 million, EPS $0.11. Guidance raised.","evidence_excerpt":"First Quarter 2026 Results Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target • First Quarter 2026 Financial Results: ◦ Revenue of $1,371 million, an increase of 15% year-o ver-ye ar; 10% organic constant currency growth ◦ Reported Net Income of $57 million, Adjusted Net Income of $204 million ◦ Adjusted EBITDA of $334","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739104/000173910426000027/0001739104-26-000027-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2026"},{"label":"Revenue","value":"$1,371 million"},{"label":"Net income","value":"$57 million"},{"label":"EPS","value":"$0.11"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}